Open Access
VIEWPOINT
Analysis of tumor-draining vein secretome: A direct access to tumor-derived extracellular vesicles in surgical lung cancer patients
1 Molecular Oncology and Embryology Laboratory, Department of Surgery and Surgical Specializations, Human Anatomy Unit, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), Barcelona, 08036, Spain
2 School of Basic Medical Sciences, Chengdu University, Chengdu, 610106, China
3 Department of Thoracic Surgery, Hospital Clínic de Barcelona, Universitat de Barcelona (UB), Barcelona, 08036, Spain
4 Thoracic Oncology Unit, Hospital Clinic, Barcelona, 08036, Spain
5 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 08036, Spain
6 Department of Pneumology, Institut Clínic Respiratori (ICR), Hospital Clínic de Barcelona, Universitat de Barcelona (UB), Barcelona, 08036, Spain
7 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, 28029, Spain
* Corresponding Author: ALFONS NAVARRO. Email:
BIOCELL 2023, 47(5), 951-957. https://doi.org/10.32604/biocell.2023.027718
Received 11 November 2022; Accepted 31 January 2023; Issue published 10 April 2023
Abstract
Tumor-secreted extracellular vesicles (EVs) participate in the metastasis process through different mechanisms, including the preparation of the pre-metastatic niche to grant circulating tumor cells (CTCs) implantation and growth. The study of the metastasis process through the analysis of CTCs and tumor-derived EVs is difficult because of the dilution grade of these elements in peripheral blood. In early-stage lung cancer patients, the tumor-secreted products are even more diluted. An attractive strategy in surgical lung cancer patients is to purify them from a pulmonary tumor-draining vein where they are enriched. The information obtained from the analysis of EVs and CTCs purified from this source could give more accurate information about tumor biology and could be an important source of biomarkers to identify patients at high risk of relapse after curative surgery.Keywords
Cite This Article
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.